A Study on Pharmacokinetics and Safety of BAT2506 Injection Versus Simponi®

Summary

This is a randomized, double-blind, parallel three-arm, and single-dose Phase I clinical study, designed to compare the similarity of pharmacokinetics, safety and immunogenicity between BAT2506 Injection and Simponi® (EU-licensed and US-licensed) after single subcutaneous administration in healthy Chinese male subjects.

Timeline

Start

2022-08-01

Primary completion

2023-06-27

Completion

2023-07-10

Drugs

Indications